Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D5BMY9
|
|||
| Drug Name |
TMX-049
|
|||
| Indication | Diabetic nephropathy [ICD-11: GB61.Z; ICD-9: 250.4] | Phase 2 | [1] | |
| Company |
Teijin Pharma
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Xanthine dehydrogenase/oxidase (XDH) | Target Info | Inhibitor | [2] |
| BioCyc | Purine nucleotides degradation | |||
| Urate biosynthesis/inosine 5'-phosphate degradation | ||||
| Guanosine nucleotides degradation | ||||
| Adenosine nucleotides degradation | ||||
| Retinoate biosynthesis II | ||||
| KEGG Pathway | Purine metabolism | |||
| Caffeine metabolism | ||||
| Drug metabolism - other enzymes | ||||
| Metabolic pathways | ||||
| Peroxisome | ||||
| Panther Pathway | Adenine and hypoxanthine salvage pathway | |||
| Purine metabolism | ||||
| Pathwhiz Pathway | Caffeine Metabolism | |||
| Purine Metabolism | ||||
| Reactome | Purine catabolism | |||
| WikiPathways | Oxidative Stress | |||
| Effects of Nitric Oxide | ||||
| Metabolism of nucleotides | ||||
| Selenium Micronutrient Network | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03449199) Phase 2 Study of TMX-049 in Subjects With Type 2 Diabetes and Albuminuria. U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of Teijin Pharma. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.